TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27787269
Drug: ATX-101 2
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 2 mg/cm
Study: 27787269
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and injectable lidocaine
Study: 27787269
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and loratadine
Study: 27787269
Drug: ATX-101 treatment
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATX-101 treatment
Study: 22003214
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (25 mL) injected cephalad to the peroneal-tibial division (Group A)
Study: 22003214
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (25 mL) injected caudad to the peroneal-tibial division (Group B)
Study: 10941879
Drug: CLA supplementation
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA supplementation (3 g/d)
Study: 1464274
Drug: Slow discontinuation
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow discontinuation of antiepileptic drugs (AEDs)
Study: 1464274
Drug: Routine maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine maintenance of antiepileptic drugs (AEDs)
Study: 28641407
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day and atorvastatin 20 mg/day
Study: 25621239
Drug: Intranasal splints
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal splints after PIT (Group A)
Study: 25621239
Drug: No intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intranasal splints after PIT (Group B)
Study: 21674711
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of symptom assessment plus endoscopic evidence of recurrence
Study: 19506137
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic sodium chloride solution infusion)
Study: 16469978
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (3.6 g n‐3 fatty acids/d)
Study: 11685167
Drug: Amiodarone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (1 g/d intravenously for 48 hours, then 400 mg/d orally until discharge)
Study: 11685167
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg intravenously every 6 hours for 48 hours, then 20 mg orally four times a day until discharge)
Study: 9799348
Drug: Pethidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (100 mg by intramuscular injection)
Study: 9799348
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg by intramuscular injection)
Study: 3180632
Drug: Bumetanide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (3 mg oral and intravenous doses)
Study: 30742566
Drug: Duvelisib 25
Normalized name: duvelisib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib 25 mg orally twice daily
Study: 3598997
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg twice daily for 4 weeks
Study: 3891346
Drug: Nifedipine treatment
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine treatment
Study: 3598997
Drug: Longterm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longterm treatment (16-20 weeks) with Nifedipine
Study: 8402326
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 3 months
Study: 29690916
Drug: Combined protocol
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined protocol for the treatment of SAM and MAM
Study: 29690916
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol (national treatment protocol)
Study: 24213958
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (anodal stimulation of the motor cortex, 10 days, 20 minutes, 2 mA, twice a day)
Study: 19174493
Drug: Capromorelin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capromorelin (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day)
Study: 19174493
Drug: Capromorelin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capromorelin (various doses)
Study: 16300168
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg with Lovastatin 40 mg
Study: 16300168
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg with Atenolol 100 mg
Study: 16300168
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg with Celecoxib 200 mg
Study: 16300168
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg with Cimetidine 800 mg
Study: 7714229
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral SDZ ENS-163 with intravenous saline
Study: 7714229
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with intravenous scopolamine
Study: 7714229
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral SDZ ENS-163 with intravenous scopolamine
Study: 7714229
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo with intravenous saline
Study: 30476258
Drug: Clinic-community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-community treatment program (Bull City Fit)
Study: 30476258
Drug: Clinic-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-only treatment program
Study: 1012648
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment programs
Study: 12953725
Drug: Sufentanil 1
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1 microg/ml in normal saline (Group S)
Study: 12953725
Drug: Sufentanil 1
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1 microg/ml with bupivacaine 0.125% (Group SB)
Study: 7677723
Drug: Imagery rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery rehearsal treatment
Study: 2288408
Drug: Tramadol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (0.5 mg/kg)
Study: 7015174
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of kanamycin 500 mg plus clindamycin 600 mg intramuscularly
Study: 30992395
Drug: WEB implant
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB implant
Study: 21226941
Drug: Multifamily group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifamily group psychoeducation (MFG) with concurrent cognitive remediation
Study: 8836264
Drug: Ketoprofen 300
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 300 mg (bolus followed by continuous infusion)
Study: 1417380
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (0.1 mg/24 h for 4 days, then 0.2 mg/24 h for 3 days, continued for 6 weeks after target quit day)
Study: 2666565
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine
Study: 6719387
Drug: Dipyridamole (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (375 mg/d)
Study: 6719387
Drug: RA 233
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RA 233 (1500 mg/d)
Study: 27085624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Epirubicin (EPI) and Interferon-α2a (IFN)
Study: 20720535
Drug: Oxytocin (OXT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OXT) 24 IU or 40.32 μg
Study: 16158782
Drug: Nasal budesonide
Normalized name: budesonide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal budesonide plus oral zafirlukast twice a day
Study: 16158782
Drug: Nasal budesonide
Normalized name: budesonide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal budesonide plus oral loratadine/pseudoephedrine twice a day
Study: 12043956
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg (Avandia tablets, 4 mg x 2)
Study: 12043956
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg after pretreatment with sucralfate 2 g (Recolfate tablets, 1 g x 2)
Study: 8162670
Drug: Disulfiram (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (500 mg orally)
Study: 31016613
Drug: Leflunomide 10
Normalized name: leflunomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide 10 mg
Study: 7488280
Drug: Leflunomide 25
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide 25 mg
Study: 7488280
Drug: Leflunomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (10 mg and 25 mg)
Study: 2148849
Drug: Ridogrel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridogrel (2 x 300 mg per day for 2 1/2 days)
Study: 2148849
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 x 300 mg per day for 2 1/2 days)
Study: 7016067
Drug: Cimetidine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (various doses)
Study: 7016067
Drug: Cimetidine (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (2,400 mg/day)
Study: 25855055
Drug: Oral consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral consumption of Respecta(®) complex (L. acidophilus La‐14, L. rhamnosus HN001, and bovine lactoferrin) twice daily for 2 weeks
Study: 25855055
Drug: Oral consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral consumption of Respecta(®) complex
Study: 22473713
Drug: Vaniprevir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaniprevir (300 mg BID, 600 mg BID, 600 mg QD, or 800 mg QD)
Study: 17329659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vaccine Day and educational campaign
Study: 17329659
Drug: Vaccine Day
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Day alone
Study: 15334330
Drug: Naloxone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (8 mg, four times daily via gastric tube)
Study: 3384588
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of pyridoxine-HCl daily supplementation for one year
Study: 27550387
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) as add-on therapy
Study: 14687872
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (150 mg/day)
Study: 9177952
Drug: Moclobemide 600
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 600 mg per day
Study: 9177952
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg per day
Study: 8479230
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg three times per day for the first month, then 100 mg three times per day for the next two months
Study: 2870610
Drug: 2% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nitroglycerin gel adhesive administered transdermally by an adhesive (Topinitro), 2.5‐10 mg/day, individually titrated for 28 days
Study: 2843039
Drug: Enhanced-potency inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced-potency inactivated polio vaccines
Study: 26870801
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine
Study: 14506371
Drug: Inactivated polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated polio vaccine
Study: 31050931
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment
Study: 31373272
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (Space from Depression), delivered over 8 weeks, 7 modules.
Study: 28661316
Drug: 50 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/d soya protein
Study: 28661316
Drug: 25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/d soya protein
Study: 28661316
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g/d soya protein)
Study: 23839277
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (10 µg) with 2.6 ml of 0.5% hyperbaric bupivacaine (13 mg)
Study: 23839277
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 2.8 ml of 0.5% hyperbaric bupivacaine (14 mg)
Study: 21703206
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg/day from week 20 to 32 of gestation (n=135)
Study: 19345439
Drug: Telbivudine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine treatment
Study: 19307526
Drug: Metformin hydrochloride,
Normalized name: MetFORMIN Hydrochloride, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin hydrochloride, 850 mg, added to insulin therapy (1-3 times daily)
Study: 2246698
Drug: Exosurf (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (5 ml/kg dose)
Study: 27552585
Drug: High-dose intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intranasal oxytocin (32 IU per day)
Study: 27552585
Drug: Low-dose intranasal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intranasal oxytocin (16 IU per day)
Study: 25712685
Drug: Rilotumumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (15 mg/kg) plus epirubicin, cisplatin, and capecitabine (ECX)
Study: 25712685
Drug: Rilotumumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (7.5 mg/kg) plus ECX
Study: 11078982
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement (2 IU GH/m daily for 4 months)
Study: 8862480
Drug: Vitamins (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (vitamin E, 15 mg and vitamin C, 120 mg) and beta-carotene, 6 mg
Study: 8862480
Drug: Trace elements
Normalized name: trace elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace elements (zinc, 20 mg, selenium, 100 micrograms)
Study: 1799477
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b in a dose of 5 million units (MU) three times per week
Study: 27647873
Drug: Eluxadoline 300
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eluxadoline 300 mg
Study: 27647873
Drug: Eluxadoline 100
Normalized name: eluxadoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline 100 mg (intranasal)
Study: 27647873
Drug: Eluxadoline 200
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eluxadoline 200 mg (intranasal)
Study: 27647873
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral study)
Study: 27647873
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal study)
Study: 20230454
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg amitriptyline
Study: 18383000
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg paroxetine
Study: 20550020
Drug: Pramipexole 0.25
Normalized name: pramipexole 0.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.25 mg
Study: 12682318
Drug: L-dopa therapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa therapy
Study: 12682318
Drug: L-dopa-naive (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa-naive (control group)
Study: 9441116
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment in IPF patients
Study: 6391270
Drug: Innovar (fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovar (fentanyl and droperidol, 2.5-5 ml)
Study: 22653705
Drug: Atopaxar (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopaxar (50, 100, or 200 mg daily)
Study: 18562985
Drug: Diaphragm with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm with placebo gel (HEC)
Study: 15653582
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (balloon angioplasty alone or stenting)
Study: 15653582
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with severe stenosis
Study: 12419136
Drug: 25% metronidazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% metronidazol gel
Study: 28008557
Drug: Conventional decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional decongestive therapy
Study: 25044235
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of insulin 0.1U • kg‐1 • h‐1
Study: 1728908
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction and placebo drug treatment
Study: 3768929
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of chlorthalidone
Study: 2831525
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of atenolol
Study: 31660991
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg (CAFF300)
Study: 31660991
Drug: TeaCrine® 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TeaCrine® 300 mg (TEA300)
Study: 31660991
Drug: TeaCrine® +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TeaCrine® + Caffeine (COMBO; 150 mg/150 mg)
Study: 31660991
Drug: Placebo 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300 mg (PLA)
Study: 23031354
Drug: Low glucose
Normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glucose (LG; 2.5 mg/kg per minute)
Study: 11981396
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg oral tablet taken three times per day)
Study: 11981396
Drug: Cinnarizine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (150 mg oral capsule taken once daily with dinner)
Study: 7255508
Drug: Meptazinol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (1 mg/kg)
Study: 31845894
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy (23-month duration after one month of DAPT)
Study: 31845894
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment (12-month DAPT followed by 12 months of aspirin)
Study: 27106272
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment
Study: 31150789
Drug: Sesame Oral
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame Oral Immunotherapy (OIT)
Study: 22848592
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain therapy procedures
Study: 20354543
Drug: Dose-dense administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense administration of paclitaxel
Study: 20354543
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of platinum and paclitaxel
Study: 20354543
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of pegylated liposomal doxorubicin combined with carboplatin
Study: 16169422
Drug: Enoxaparin 80
Normalized name: ENOXAPARIN 80MG/0.8ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 80 mg/day
Study: 12471862
Drug: Arthritis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthritis treatment
Study: 12471862
Drug: Diabetes treatment
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes treatment
Study: 19809365
Drug: Hypertension treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension treatment
Study: 9472846
Drug: Fluoxetine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (5-10 mg/day)
Study: 7611312
Drug: Topical medication
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medication first
Study: 2203250
Drug: High-fat evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-fat evening meal (41 g fat)